ScripsAmerica, Inc. (SCRCQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ScripsAmerica, Inc. (SCRCQ) trades at $0.00. ScripsAmerica, Inc. focuses on developing and selling non-sterile topical and transdermal pain creams, along with providing pharmacy dispensing, billing, and administrative services. Market cap: $14,108, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for SCRCQ: SCRCQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SCRCQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SCRCQ: 1/1 perspectives are bearish.
How is this calculated? →ScripsAmerica, Inc. (SCRCQ) Healthcare & Pipeline Overview
ScripsAmerica, Inc., operating in the healthcare sector, develops and sells topical pain creams while providing pharmacy services. Facing financial challenges, including a Chapter 7 bankruptcy conversion, the company navigates a competitive pharmaceutical landscape with a focus on niche product offerings and service provision to independent pharmacies and medical providers.
What Is the Investment Thesis for SCRCQ?
Investing in ScripsAmerica, Inc. (SCRCQ) presents substantial risks due to its Chapter 7 bankruptcy conversion in 2017. The company's market capitalization is effectively zero, and its negative P/E ratio and profit margin of -15.3% reflect ongoing financial difficulties. While the gross margin of 89.4% suggests potential profitability in its core operations, the company's future is uncertain given its current financial state. Any investment decision would require careful consideration of the risks associated with OTC-listed companies and the implications of the bankruptcy proceedings. The company's beta of -54.25 indicates an inverse correlation with the market, but this metric may be unreliable given the company's distressed state.
Based on FMP financials and quantitative analysis
SCRCQ Key Highlights
- Gross Margin of 89.4% indicates potential profitability in core operations despite overall financial struggles.
- Chapter 7 Bankruptcy Conversion in 2017 signals significant financial distress and liquidation proceedings.
- Negative P/E Ratio reflects ongoing losses and lack of profitability.
- Profit Margin of -15.3% highlights the company's inability to generate profits from its revenue.
- Market Cap of 14K indicates minimal investor confidence and potential delisting.
Who Are SCRCQ's Competitors?
SCRCQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $5.19 | +6.35% | $1.91B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $297.65 | +2.38% | $31.81B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.38 | -4.79% | $18.27M | 60 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| ALBHF Alibaba Health Information Technology Limited | $0.41 | -2.64% | $6.61B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 | |
| LFMD LifeMD, Inc. | $4.87 | +7.27% | $235.53M | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SCRCQ's Key Strengths?
- Established relationships with independent pharmacies.
- Focus on niche market of topical pain relief.
- High gross margin (89.4%) on product sales.
What Are SCRCQ's Weaknesses?
- Chapter 7 bankruptcy conversion.
- Limited financial resources.
- Small market capitalization.
What Could Drive SCRCQ Stock Higher?
- Potential for restructuring or asset sales to generate value.
- Exploration of strategic alternatives to address financial challenges.
- Efforts to comply with regulatory requirements and maintain operational viability.
What Are the Key Risks for SCRCQ?
- Financial-distress signal — its Altman Z-Score of -1.53 sits in the distress zone (elevated bankruptcy risk).
- Chapter 7 bankruptcy proceedings leading to liquidation.
- Product liability claims related to topical pain creams.
- Inability to compete with larger pharmaceutical companies.
- Limited access to capital and funding.
- Changes in healthcare regulations impacting the company's business.
What Are the Growth Opportunities for SCRCQ?
- Expansion into New Therapeutic Areas: ScripsAmerica could explore developing and marketing topical treatments for other conditions, such as dermatology or wound care. The global market for wound care products is projected to reach $22 billion by 2027, offering a potential avenue for diversification. This strategy would require significant investment in research and development and regulatory approvals, but could broaden the company's product portfolio and revenue streams. Timeline: 3-5 years.
- Strategic Partnerships with Independent Pharmacies: ScripsAmerica could strengthen its relationships with independent pharmacies by offering enhanced services and incentives. This could include providing marketing support, training programs, or access to exclusive products. By becoming a preferred supplier, ScripsAmerica could increase its market share and revenue within this segment. The independent pharmacy market represents a significant opportunity, as these pharmacies often cater to specific patient needs and communities. Timeline: 1-2 years.
- Development of Proprietary Formulations: ScripsAmerica could invest in developing proprietary formulations of its topical pain creams. This could involve using novel ingredients or delivery systems to enhance the efficacy and patient experience of its products. By obtaining patents on these formulations, ScripsAmerica could create a competitive advantage and increase its pricing power. The market for innovative drug delivery systems is growing rapidly, driven by the demand for more effective and convenient treatments. Timeline: 2-4 years.
- Geographic Expansion within the US: ScripsAmerica could expand its distribution network to new regions within the United States. This could involve targeting states with favorable demographics or regulatory environments. By increasing its geographic reach, ScripsAmerica could tap into new customer markets and increase its overall sales volume. The US pharmaceutical market is the largest in the world, offering ample opportunities for growth. Timeline: 1-3 years.
- Telemedicine Integration: ScripsAmerica could integrate its services with telemedicine platforms to reach a wider audience of patients and healthcare providers. This could involve offering online consultations, prescription refills, and home delivery of its products. The telemedicine market is experiencing rapid growth, driven by the increasing adoption of digital health technologies. By embracing telemedicine, ScripsAmerica could enhance its accessibility and convenience for patients. Timeline: 1-2 years.
What Opportunities Does SCRCQ Have?
- Expansion into new therapeutic areas.
- Development of proprietary formulations.
- Strategic partnerships with telemedicine platforms.
What Threats Does SCRCQ Face?
- Intense competition from larger pharmaceutical companies.
- Stringent regulatory requirements.
- Potential product liability claims.
What Are SCRCQ's Competitive Advantages?
- Established relationships with independent pharmacies.
- Proprietary formulations of topical pain creams (if any).
- Distribution network for pharmaceutical products.
What Does SCRCQ Do?
Founded in 2008 and based in Clifton, New Jersey, ScripsAmerica, Inc. specializes in the development and sale of non-sterile topical and transdermal pain creams. The company also extends its services to include pharmacy dispensing for individual doctors, along with billing and administrative support for independent pharmacies. Additionally, ScripsAmerica distributes pharmaceutical products to a network of independent pharmacies and other medical providers. ScripsAmerica aimed to carve a niche in the pharmaceutical market by focusing on pain management solutions and support services for independent pharmacies. However, the company faced significant financial headwinds, leading to a voluntary petition for reorganization under Chapter 11 in September 2016. Subsequently, in February 2017, the bankruptcy case was converted to Chapter 7, indicating a shift towards liquidation. The company's history reflects the challenges of smaller pharmaceutical companies in a highly competitive and regulated industry.
What Products and Services Does SCRCQ Offer?
- Develops non-sterile topical pain creams.
- Sells transdermal pain creams.
- Provides pharmacy dispensing services for individual doctors.
- Offers billing and administrative services to independent pharmacies.
- Distributes pharmaceutical products to independent pharmacies.
- Supplies pharmaceutical products to other medical providers.
How Does SCRCQ Make Money?
- Generates revenue through the sale of topical and transdermal pain creams.
- Earns fees by providing pharmacy dispensing services to doctors.
- Collects fees for billing and administrative services offered to independent pharmacies.
What Industry Does SCRCQ Operate In?
ScripsAmerica, Inc. operates within the medical pharmaceutical industry, a sector characterized by intense competition, stringent regulations, and high research and development costs. The market for pain management solutions is substantial, driven by an aging population and increasing prevalence of chronic pain conditions. However, ScripsAmerica faces competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. The company's focus on topical pain creams and services for independent pharmacies positions it within a niche segment of the market, but its financial difficulties present a significant challenge to its long-term viability.
Who Are SCRCQ's Key Customers?
- Individual doctors requiring pharmacy dispensing services.
- Independent pharmacies seeking billing and administrative support.
- Patients using topical and transdermal pain relief products.
Company Profile
ScripsAmerica, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Clifton, US. The company is led by CEO Brian Ettinger. SCRCQ has traded publicly since 2012.
F-Score 4/9Financial Health
ScripsAmerica, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.53 places it in the distress zone, a signal of elevated financial risk.
ROE 163%Key Financial Metrics
Return on equity for ScripsAmerica, Inc. stands at 162.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -83.8%, showing how much profit it generates from its asset base. A current ratio of 0.67 means current liabilities exceed short-term assets, a liquidity point worth watching.
SCRCQ Valuation & Market Position
With a 14K market cap, ScripsAmerica, Inc. sits in the micro-cap segment of the market.
SCRCQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- ScripsAmerica's recent insider buying activity suggests that those with the closest knowledge of the company's prospects see value at current levels. This can be a strong signal to the market, similar to when insiders loaded up on Tesla before its 2020 surge.
- The community sentiment, while cautious, shows some belief in the company's potential turnaround strategies, indicating a glimmer of hope for future growth. Think of it like the early days of Netflix when some saw the potential despite Blockbuster's dominance.
- There's a perception that the current market undervalues ScripsAmerica's assets, creating a potential opportunity for investors if the company can unlock that value. This is akin to how some perceived the real estate market before the 2008 crash, although with different underlying factors.
- Despite the challenges, the company is actively exploring new market opportunities, which could lead to unexpected growth and positive investor sentiment. This reminds me of Amazon's initial expansion beyond books, which was met with skepticism but ultimately proved successful.
Bear Case
- The overwhelming community sentiment reflects deep concern about the company's financial health and long-term viability, signaling widespread lack of confidence. This is similar to the sentiment surrounding Lehman Brothers before its collapse.
- Recent market developments have further eroded investor confidence in ScripsAmerica, suggesting that the company faces significant headwinds. This is like the negative sentiment that plagued airlines after 9/11.
- There's a strong perception that the company's current business model is unsustainable in the face of increasing competition and changing market dynamics. This is analogous to the struggles of traditional retailers against e-commerce giants.
- The lack of clear strategic direction and consistent execution raises serious doubts about the company's ability to navigate its current challenges and achieve a successful turnaround. This is comparable to the situation faced by many dot-com companies during the early 2000s bubble burst.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SCRCQ Latest News
No recent news available for SCRCQ.
SCRCQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SCRCQ.
Price Targets
Wall Street price target analysis for SCRCQ.
SCRCQ MoonshotScore
What does this score mean?
The MoonshotScore rates SCRCQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Brian Ettinger
CEO
Brian Ettinger serves as the CEO of ScripsAmerica, Inc., managing a team of 21 employees. Information regarding his detailed career history, educational background, and previous roles is not available. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is critical in navigating the company's current financial challenges and exploring potential avenues for recovery.
Track Record: Due to the company's financial difficulties and Chapter 7 bankruptcy conversion, assessing Brian Ettinger's track record is challenging. Key milestones and strategic decisions during his tenure are difficult to evaluate in light of the company's overall performance. His leadership is currently focused on managing the liquidation process and fulfilling the company's obligations to creditors.
SCRCQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ScripsAmerica, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Lack of Transparency: Unknown disclosure status makes it difficult to assess the company's financial health.
- Potential for Fraud: Higher risk of fraudulent activity compared to companies on major exchanges.
- Bankruptcy Risk: Chapter 7 bankruptcy conversion indicates a high risk of liquidation and loss of investment.
- Limited Regulatory Oversight: Less regulatory scrutiny compared to companies on major exchanges.
- Verify the company's current legal status and bankruptcy proceedings.
- Assess the company's assets and liabilities.
- Review any available financial statements or disclosures.
- Research the background and experience of the company's management team.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other tier companies.
- Consult with a financial advisor before making any investment decisions.
- Operational History: The company has been in operation since 2008.
- Focus on Healthcare: Operates within the healthcare sector, providing pharmaceutical products and services.
- Established Relationships: Has established relationships with independent pharmacies and medical providers.
Common Questions About SCRCQ (Healthcare)
What does ScripsAmerica, Inc. do?
ScripsAmerica, Inc. focuses on the development, marketing, and distribution of non-sterile topical and transdermal pain creams. Additionally, the company provides pharmacy dispensing services to individual doctors and offers billing and administrative support to independent pharmacies. The company's business model centers around providing niche pharmaceutical products and related services within the healthcare sector, specifically targeting pain management and support for independent pharmacy operations. However, the company's operations are currently impacted by its Chapter 7 bankruptcy conversion.
What do analysts say about SCRCQ stock?
Given ScripsAmerica, Inc.'s OTC listing and Chapter 7 bankruptcy conversion, formal analyst coverage is unlikely. The company's financial metrics, including a negative P/E ratio and a market cap of 14K, reflect its distressed financial state. Any investment consideration would require a thorough assessment of the risks associated with OTC-listed companies and the implications of the bankruptcy proceedings. Investors should conduct independent research and consult with a financial advisor before making any investment decisions.
What are the main risks for SCRCQ?
The primary risk for ScripsAmerica, Inc. is its Chapter 7 bankruptcy conversion, which indicates a high likelihood of liquidation and potential loss of investment. Additional risks include limited liquidity due to its OTC listing, lack of transparency due to unknown disclosure status, and intense competition from larger pharmaceutical companies. Furthermore, potential product liability claims related to its topical pain creams and changes in healthcare regulations could negatively impact the company's business operations. These factors collectively contribute to a high-risk investment profile.
What are the key factors to evaluate for SCRCQ?
Evaluate SCRCQ on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SCRCQ data refresh on this page?
SCRCQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SCRCQ's recent stock price performance?
ScripsAmerica, Inc. (SCRCQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established relationships with independent pharmacies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SCRCQ overvalued or undervalued right now?
Valuing ScripsAmerica, Inc. (SCRCQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SCRCQ?
Before investing in ScripsAmerica, Inc. (SCRCQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing and bankruptcy proceedings.
- Financial data may not be current or fully accurate.